卫材披露FY2026一季度收入2343亿日元、经营利润247亿日元，股价已下跌3.56%

Trump says Iran talks to begin on Monday amid cycle of threats and pullbacks
Introduction & Market Context
Eisai Co., Ltd. (TYO:4523) presented its Q1 FY2026 financial results on August 3, 2026, reporting double-digit revenue and operating profit growth driven by strong performance across its three key growth products—LENVIMA, DAYVIGO, and LEQEMBI. Despite beating revenue forecasts by approximately 9.5%, the company’s shares fell 3.56% to $4,656, suggesting investor caution around rising expenses and the pace of LEQEMBI adoption.
The Japanese pharmaceutical company reported revenue of JPY 234.3 billion, representing a 15.6% year-over-year increase and reaching 27% of its full-year forecast of JPY 883.5 billion. Operating profit climbed 19.2% to JPY 24.7 billion, achieving 35% of the annual target and indicating stronger-than-expected profitability in the quarter.
Quarterly Performance Highlights
Eisai’s pharmaceutical business generated JPY 230.9 billion in revenue, up 16.4% year-over-year, accounting for 98.5% of total company revenue. The following chart illustrates the company’s key financial metrics for the quarter:
The consolidated income statement reveals robust growth across multiple metrics. As detailed in the financial breakdown below, gross profit increased 14.5% to JPY 183.2 billion, maintaining a healthy gross margin of 78.2%. Net profit attributable to owners rose 26.0% to JPY 18.2 billion, with earnings per share reaching JPY 64.71.
Operating expenses increased in line with growth ambitions, with R&D expenses rising 12.7% to JPY 43.7 billion and SG&A expenses climbing 14.6% to JPY 114.8 billion. Notably, profit-sharing expenses for LENVIMA paid to Merck increased JPY 8.2 billion to JPY 44.3 billion, reflecting the product’s strong sales performance.
Management highlighted that the company achieved profitability in its commercial businesses for the first time when excluding LEQEMBI R&D spending, marking a significant operational milestone.
3L Products Drive Growth
The company’s three major growth products—collectively referred to as "3L"—generated combined revenue of JPY 145.5 billion, up 20.5% year-over-year. The following waterfall chart breaks down the revenue increase drivers:
The pharmaceutical business contributed JPY 24.8 billion from 3L products and JPY 7.7 billion from other products, with LENVIMA adding JPY 13.4 billion, DAYVIGO contributing JPY 5.2 billion, and LEQEMBI providing JPY 6.2 billion to the growth.
Similarly, operating profit growth was driven primarily by the 3L portfolio, as illustrated in this analysis:
Gross profit increased JPY 23.2 billion due to pharmaceutical business expansion, while R&D expenses rose JPY 4.9 billion to support continued investment in LEQEMBI and the anti-MTBR tau antibody etalanetug. SG&A expenses increased JPY 14.7 billion, including JPY 8.2 billion in higher LENVIMA profit-sharing and JPY 2.6 billion in proactive LEQEMBI investments.
LENVIMA Maintains Market Leadership
LENVIMA, Eisai’s oral multi-kinase inhibitor with seven indications across five cancer types, generated revenue of JPY 97.3 billion in Q1, up 16% year-over-year. The product has contributed to treating approximately 620,000 patients in 83 countries since its launch 11 years ago.
The regional revenue breakdown shows strong U.S. performance:
The Americas region contributed JPY 66.5 billion, up from JPY 58.1 billion in the prior year, driven by solid demand across all tumor types. LENVIMA maintains top share within the tyrosine kinase inhibitor category for advanced renal cell carcinoma, advanced endometrial carcinoma, advanced hepatocellular cancer, and radioactive iodine-refractory differentiated thyroid cancer.
A new indication is under U.S. FDA review for certain advanced renal cell carcinoma patients whose disease has progressed after anti-PD-1/L1 therapy, based on LITESPARK-011 study results combining WELIREG with LENVIMA. The PDUFA date is set for October 4, 2026.
DAYVIGO Accelerates Global Expansion
DAYVIGO, an orexin receptor antagonist for insomnia treatment, achieved revenue of JPY 18.9 billion, marking 38% year-over-year growth. The product is approved in 29 countries and territories, including Japan and the U.S.
Regional performance demonstrates broad-based momentum:
In Japan, DAYVIGO maintained the number one market share in both sales and patient volume within the dual orexin receptor antagonist market. The Americas region saw revenue increase to JPY 3.3 billion from JPY 1.9 billion, while China contributed JPY 1.4 billion, up from just JPY 0.1 billion in the prior year.
The company completed regulatory submissions in the UK and EU in July 2026, positioning DAYVIGO for further geographic expansion.
LEQEMBI Strategic Initiatives
LEQEMBI, Eisai’s anti-amyloid beta antibody for early Alzheimer’s disease, generated JPY 29.3 billion in Q1 revenue, up 27% year-over-year. The product is approved in 53 countries and territories for treating early AD.
The regional revenue composition shows continued U.S. growth:
The Americas contributed JPY 15.5 billion, up 70.5% year-over-year, supported by increases in patients with early AD and blood-based biomarker testing volumes. LEQEMBI IQLIK, a subcutaneous auto-injector formulation, received U.S. approval for initiation treatment on July 13, 2026, representing a significant advancement in treatment convenience.
The new formulation offers administration optionality, as illustrated in this product overview:
LEQEMBI IQLIK enables at-home administration, reducing the burden of clinic visits and IV infusion dependency. Evidence presented at AAIC 2026 showed that once-weekly subcutaneous administration demonstrated similar exposure, clinical efficacy, and biomarker benefits to IV administration, with 94% of users finding the device "easy or very easy to use without help."
Eisai outlined three key foundations for leveraging LEQEMBI IQLIK’s dosing convenience:
The strategy focuses on streamlining coverage and reimbursement, standardizing testing and benefits verification, and strengthening patient support for at-home administration. Management expects LEQEMBI IQLIK for initiation treatment to launch in the U.S. in late August 2026, with Medicare Part D formulary listing anticipated in 2027.
Real-world evidence supports the long-term treatment value proposition. Data from the LEADER study of 432 patients with early AD across 13 U.S. clinical practices, presented at AAIC 2026, demonstrated compelling clinical benefits:
Among evaluable patients, 82.5% were stable or improved, with a treatment retention rate of 86.6%. Safety observations were consistent with the FDA-approved label, with ARIA observed in 12.3% of patients and no treatment-related deaths reported. Among patients treated for more than 18 months, 78.9% transitioned to maintenance treatment and remained on therapy.
The evolution of the diagnostic pathway through blood-based biomarkers represents another key growth enabler:
BBM adoption is expanding patient access through minimally invasive testing and shortening the diagnostic pathway by increasing amyloid positivity rates and optimizing PET/CSF use. In the U.S., BBM tests for amyloid confirmatory diagnosis and triage grew 75% in FY2025, with projections showing BBM adoption reaching approximately 50% of confirmatory diagnoses by FY2028, up from 15% in FY2025.
Pipeline Advancement
Eisai’s next-generation drug discovery efforts focus on the AD continuum and orexin pathway platform. The company presented significant progress on etalanetug, an investigational anti-tau antibody targeting MTBR-tau:
Clinical data from Study 103 in patients with dominantly inherited Alzheimer’s disease (DIAD) demonstrated an 89% reduction in CSF eMTBR-tau243 by 9 months and a greater than 90% reduction in plasma eMTBR-tau243. Changes in tau PET showed progression suppression or a trend toward reduction, confirming proof of mechanism.
The Tau NexGen Phase II/III study evaluating etalanetug as add-on to LEQEMBI in preclinical to early AD patients is ongoing, with topline data expected in FY2028. A separate Phase II study (Study 202) in sporadic AD patients expects topline data in FY2027.
The comprehensive pipeline overview shows multiple programs advancing across neurodegeneration, orexin pathway, and oncology:
Key pipeline milestones include LEQEMBI regulatory decisions in Japan and China (Q2 and Q4 FY2026-FY2027), ledasorexton topline data in narcolepsy (FY2026), and LENVIMA regulatory decisions for the new renal cell carcinoma indication.
Forward-Looking Statements
Eisai maintained its full-year FY2026 revenue forecast of JPY 883.5 billion and operating profit forecast of JPY 70.0 billion. The company’s progress toward these targets—27% for revenue and 35% for operating profit—suggests pacing ahead of a linear trajectory.
Product-specific forecasts include LENVIMA revenue of JPY 345.0 billion, DAYVIGO revenue of JPY 73.5 billion, and LEQEMBI revenue of JPY 143.5 billion. Management emphasized that technological innovations including LEQEMBI IQLIK and blood-based biomarkers are expected to support achievement of these targets.
The company articulated an aspirational goal of "making AD a curable disease" through two strategic approaches: initiating treatment at the presymptomatic stage with LEQEMBI to prevent amyloid accumulation, and halting disease progression by suppressing tau pathology propagation with etalanetug.
Despite the strong operational performance, the 3.56% stock decline to $4,656 suggests investors are weighing heavy spending increases against the timeline for returns on LEQEMBI infrastructure investments. The shares remain approximately 12.9% below their 52-week high of $5,349, though they have gained 27.2% from their 52-week low of $3,660.
Management concluded the presentation by stating the company aims to "drive sustainable corporate value enhancement through the dual engines of 3L growth and next-generation drug discovery," positioning Eisai for continued expansion in neurology and oncology markets.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.